<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01905956</url>
  </required_header>
  <id_info>
    <org_study_id>INQ/010013</org_study_id>
    <nct_id>NCT01905956</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of IQP- AK-102 in Reducing Body Weight</brief_title>
  <official_title>Double-blind, Randomized, Placebo-controlled, Bicentric Clinical Investigation to Evaluate Safety and Efficacy of IQP- AK-102 in Reducing Body Weight in Overweight and Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InQpharm Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InQpharm Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The individual ingredients in IQP-AK-102 have been widely used. Backed by data from several
      studies demonstrating their efficacy, we are conducting this study to look into the efficacy
      and safety of this novel combination of three fibres, in appetite regulation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Appetite regulation plays an important role in determining the food intake, which is a
      complex process influenced by biological, behavioral and environmental stimuli. Satiation
      (intrameal satiety) is defined as the process of feeling full and subsequently stopping food
      consumption during eating, it therefore reduces hunger and limits the energy consumptions
      during meals. On the other hand, satiety or more precisely intermeal satiety, delays the
      onset and possibly reduces the consumption of the next meal. High viscosity and bulking food
      components such as dietary fibre are expected to elicit stronger satiation/satiety than
      macronutrients or clear liquid.

      Due to its unique physicochemical properties, dietary fibre has been recognized as a
      potential ingredient that helps to enhance the sensation of satiety in the upper gut by
      increasing gastric distension and delaying gastric emptying, which subsequently reduces the
      food intake, and eventually leading on to weight loss.

      The investigational product is formulated from IQP-AK-102, a proprietary, patent pending
      combination of three soluble fibres. In-vitro studies showed synergistic properties for the
      fibres in IQP-AK-102. When consumed orally, IQP-AK-102 capsules dissolve in the stomach to
      release the fibres. Once hydrated, the fibres swell to form a thick, viscous and indigestible
      gel structure in the stomach. This physical structure results in increased gastric distension
      and delays the gastric emptying that induces satiety and fullness.

      However the unique composition of IQP-AK-102 had not been evaluated in human clinical
      studies. The objective of this placebo controlled, double blind study was to confirm the
      benefit of IQP-AK-102 in weight loss through promoting satiety and managing appetite. In this
      study, 120 overweight and obese subjects (60 per study arm) were tested to investigate if
      IQP-AK-102 is effective in reducing body weight over a period of 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Body Weight From Baseline to Week 12</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Body weight (kg) was measured in subjects wearing underwear and no shoes using calibrated weighing scales (Tanita BC-420 SMA).
Results were reported as value at baseline minus value at week-12, ie. amount of weight loss in (kg) (positive values).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Waist and Hip Circumference (cm) From Baseline to Week 12</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Waist circumference (cm) was measured at the level midway between the lateral lower rib margin and the iliac crest.
Hip circumference (cm) was measured as the maximal circumference over the buttocks.
Results were reported as value at baseline minus value at week-12, ie. amount of waist and hip circumference reduction (cm) (positive values).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Body Fat Content (%) From Baseline to Week 12</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Body fat content (%) was measured by bio-impedance method using validated electronic weighing scales (Tanita BC-420 SMA).
Results were reported as value at baseline minus value at week-12, ie. reduction of body fat content (%) (positive values).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Body Fat Mass (kg) From Baseline to Week 12</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Body fat mass kg) was measured by bio-impedance method using validated electronic weighing scales (Tanita BC-420 SMA).
Results were reported as value at baseline minus value at week-12, ie. reduction of body fat mass kg) (positive values).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food Craving Questionnaire (FCQ)</measure>
    <time_frame>Baseline and 4, 8, and 12 weeks</time_frame>
    <description>This validated questionnaire evaluates changes in food cravings. It contains 15 items and was completed by the subjects based on the momentary feeling at the study site during visits 2 to 5 (Baseline and week 4, 8 and 12). Assessment was based on the following 5-point Likert scale:
= I do not agree at all
= I do not agree
= Neutral
= I agree
= I highly agree
Results were expressed as the mean score for the whole population in the respective intervention group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Evaluation of Efficacy by the Investigators</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Evaluation of Efficacy by the Subjects</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Evaluation of Safety by the Investigators</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Evaluation of Safety by the Subjects</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Weight Loss</condition>
  <arm_group>
    <arm_group_label>IQP-AK-102</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 capsules per dose, three times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 capsules per dose, 3 times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>IQP-AK-102</intervention_name>
    <description>IQP-AK-102 was presented in the form of a capsule containing proprietary, patent pending combination of three soluble fibres and excipients.</description>
    <arm_group_label>IQP-AK-102</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo contained microcrystalline cellulose and other excepients. Both active and placebo capsules had identical physical appearance in terms of size, shape, colour and opacity.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 65 years

          -  25≤BMI≤35

          -  Expressed desire for weight loss

          -  Accustomed to 3 main meals/day

          -  Generally in good health

          -  Consistent and stable body weight 3 months prior to study enrolment

          -  Consistent regular physical activity

          -  Commitment to avoid the use of other weight loss products during study

          -  Commitment to adhere to diet and lifestyle recommended for the study

        Exclusion Criteria:

          -  Known sensitivity to the ingredients of the device

          -  Presence of any active gastrointestinal disease

          -  Malabsorption disorders

          -  Pancreatitis

          -  Stenosis in the GI tract

          -  Bariatric surgery

          -  Any other reason deemed suitable for exclusion, per investigator's judgement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Udo Bongartz</last_name>
    <role>Principal Investigator</role>
    <affiliation>analyze &amp; realize GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Grube</name>
      <address>
        <city>Berlin</city>
        <zip>10709</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2013</study_first_submitted>
  <study_first_submitted_qc>July 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2013</study_first_posted>
  <results_first_submitted>January 4, 2016</results_first_submitted>
  <results_first_submitted_qc>February 10, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 8, 2016</results_first_posted>
  <last_update_submitted>February 10, 2016</last_update_submitted>
  <last_update_submitted_qc>February 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IQP-AK-102</title>
          <description>2 capsules per dose, three times daily
IQP-AK-102</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>2 capsules per dose, 3 times daily
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60">Randomized</participants>
                <participants group_id="P2" count="59">Randomized</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intention-to-treat Population</title>
              <participants_list>
                <participants group_id="P1" count="57">Intention-to-treat population</participants>
                <participants group_id="P2" count="54">Intention-to-treat population</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54">Per-protocol population</participants>
                <participants group_id="P2" count="48">Per-protocol population</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IQP-AK-102</title>
          <description>2 capsules per dose, three times daily
IQP-AK-102</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>2 capsules per dose, 3 times daily
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="57"/>
            <count group_id="B2" value="54"/>
            <count group_id="B3" value="111"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.9" spread="12.3"/>
                    <measurement group_id="B2" value="46.3" spread="10.5"/>
                    <measurement group_id="B3" value="47.4" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimetres (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169.3" spread="9.6"/>
                    <measurement group_id="B2" value="168.2" spread="9.0"/>
                    <measurement group_id="B3" value="168.8" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilogram (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.0" spread="12.4"/>
                    <measurement group_id="B2" value="80.8" spread="8.8"/>
                    <measurement group_id="B3" value="81.9" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kilogram per metre square (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.3" spread="2.7"/>
                    <measurement group_id="B2" value="29.0" spread="2.1"/>
                    <measurement group_id="B3" value="29.2" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist Circumference</title>
          <units>centimetres (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102.1" spread="10.8"/>
                    <measurement group_id="B2" value="98.5" spread="6.9"/>
                    <measurement group_id="B3" value="100.4" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hip Circumference</title>
          <units>centimetres (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110.2" spread="8.3"/>
                    <measurement group_id="B2" value="108.7" spread="7.8"/>
                    <measurement group_id="B3" value="109.5" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123.9" spread="9.2"/>
                    <measurement group_id="B2" value="128.1" spread="15.7"/>
                    <measurement group_id="B3" value="125.9" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.7" spread="6.2"/>
                    <measurement group_id="B2" value="81.3" spread="9.4"/>
                    <measurement group_id="B3" value="80.5" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heart Rate</title>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.6" spread="5.3"/>
                    <measurement group_id="B2" value="70.7" spread="5.5"/>
                    <measurement group_id="B3" value="70.6" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Body Weight From Baseline to Week 12</title>
        <description>Body weight (kg) was measured in subjects wearing underwear and no shoes using calibrated weighing scales (Tanita BC-420 SMA).
Results were reported as value at baseline minus value at week-12, ie. amount of weight loss in (kg) (positive values).</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IQP-AK-102</title>
            <description>2 capsules per dose, three times daily
IQP-AK-102</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 capsules per dose, 3 times daily
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Body Weight From Baseline to Week 12</title>
          <description>Body weight (kg) was measured in subjects wearing underwear and no shoes using calibrated weighing scales (Tanita BC-420 SMA).
Results were reported as value at baseline minus value at week-12, ie. amount of weight loss in (kg) (positive values).</description>
          <units>kilogram (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.53" spread="2.28"/>
                    <measurement group_id="O2" value="0.14" spread="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Waist and Hip Circumference (cm) From Baseline to Week 12</title>
        <description>Waist circumference (cm) was measured at the level midway between the lateral lower rib margin and the iliac crest.
Hip circumference (cm) was measured as the maximal circumference over the buttocks.
Results were reported as value at baseline minus value at week-12, ie. amount of waist and hip circumference reduction (cm) (positive values).</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IQP-AK-102</title>
            <description>2 capsules per dose, three times daily
IQP-AK-102</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 capsules per dose, 3 times daily
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Waist and Hip Circumference (cm) From Baseline to Week 12</title>
          <description>Waist circumference (cm) was measured at the level midway between the lateral lower rib margin and the iliac crest.
Hip circumference (cm) was measured as the maximal circumference over the buttocks.
Results were reported as value at baseline minus value at week-12, ie. amount of waist and hip circumference reduction (cm) (positive values).</description>
          <units>centimetre (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Waist Circumference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12" spread="2.99"/>
                    <measurement group_id="O2" value="0.92" spread="3.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hip Circumference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" spread="2.41"/>
                    <measurement group_id="O2" value="1.07" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Body Fat Content (%) From Baseline to Week 12</title>
        <description>Body fat content (%) was measured by bio-impedance method using validated electronic weighing scales (Tanita BC-420 SMA).
Results were reported as value at baseline minus value at week-12, ie. reduction of body fat content (%) (positive values).</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Analysis of body fat was not performed for 1 subject (placebo) due to missing data from Visit 2 - Visit 5. At Visit 1, analysis was performed for 109 subjects only. As such, short of 1 baseline date.</population>
        <group_list>
          <group group_id="O1">
            <title>IQP-AK-102</title>
            <description>2 capsules per dose, three times daily
IQP-AK-102</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 capsules per dose, 3 times daily
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Body Fat Content (%) From Baseline to Week 12</title>
          <description>Body fat content (%) was measured by bio-impedance method using validated electronic weighing scales (Tanita BC-420 SMA).
Results were reported as value at baseline minus value at week-12, ie. reduction of body fat content (%) (positive values).</description>
          <population>Analysis of body fat was not performed for 1 subject (placebo) due to missing data from Visit 2 - Visit 5. At Visit 1, analysis was performed for 109 subjects only. As such, short of 1 baseline date.</population>
          <units>Percentage of body fat (%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" spread="2.91"/>
                    <measurement group_id="O2" value="0.08" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Body Fat Mass (kg) From Baseline to Week 12</title>
        <description>Body fat mass kg) was measured by bio-impedance method using validated electronic weighing scales (Tanita BC-420 SMA).
Results were reported as value at baseline minus value at week-12, ie. reduction of body fat mass kg) (positive values).</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Analysis of body fat was not performed for 1 subject (placebo) due to missing data from Visit 2 - Visit 5. At Visit 1, analysis was performed for 109 subjects only. As such, short of 1 baseline date.</population>
        <group_list>
          <group group_id="O1">
            <title>IQP-AK-102</title>
            <description>2 capsules per dose, three times daily
IQP-AK-102</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 capsules per dose, 3 times daily
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Body Fat Mass (kg) From Baseline to Week 12</title>
          <description>Body fat mass kg) was measured by bio-impedance method using validated electronic weighing scales (Tanita BC-420 SMA).
Results were reported as value at baseline minus value at week-12, ie. reduction of body fat mass kg) (positive values).</description>
          <population>Analysis of body fat was not performed for 1 subject (placebo) due to missing data from Visit 2 - Visit 5. At Visit 1, analysis was performed for 109 subjects only. As such, short of 1 baseline date.</population>
          <units>kilogram (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="2.91"/>
                    <measurement group_id="O2" value="0.05" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Food Craving Questionnaire (FCQ)</title>
        <description>This validated questionnaire evaluates changes in food cravings. It contains 15 items and was completed by the subjects based on the momentary feeling at the study site during visits 2 to 5 (Baseline and week 4, 8 and 12). Assessment was based on the following 5-point Likert scale:
= I do not agree at all
= I do not agree
= Neutral
= I agree
= I highly agree
Results were expressed as the mean score for the whole population in the respective intervention group.</description>
        <time_frame>Baseline and 4, 8, and 12 weeks</time_frame>
        <population>The analysis is performed for all subjects of the Intention-to-treat population who answered the FCQ at all visits from v2 to v5. Missing data were appeared in 9 cases at visit v5 and additional in 8 cases at visit v4.</population>
        <group_list>
          <group group_id="O1">
            <title>IQP-AK-102</title>
            <description>2 capsules per dose, three times daily
IQP-AK-102</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 capsules per dose, 3 times daily
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Food Craving Questionnaire (FCQ)</title>
          <description>This validated questionnaire evaluates changes in food cravings. It contains 15 items and was completed by the subjects based on the momentary feeling at the study site during visits 2 to 5 (Baseline and week 4, 8 and 12). Assessment was based on the following 5-point Likert scale:
= I do not agree at all
= I do not agree
= Neutral
= I agree
= I highly agree
Results were expressed as the mean score for the whole population in the respective intervention group.</description>
          <population>The analysis is performed for all subjects of the Intention-to-treat population who answered the FCQ at all visits from v2 to v5. Missing data were appeared in 9 cases at visit v5 and additional in 8 cases at visit v4.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.65" spread="1.28"/>
                    <measurement group_id="O2" value="2.74" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" spread="0.94"/>
                    <measurement group_id="O2" value="2.47" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" spread="0.96"/>
                    <measurement group_id="O2" value="2.34" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" spread="1.08"/>
                    <measurement group_id="O2" value="2.47" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Evaluation of Efficacy by the Investigators</title>
        <time_frame>12 weeks</time_frame>
        <population>The analysis is performed for all subjects of the Intention-to-treat population who answered the questions for the assessment. However, missing data still appeared.</population>
        <group_list>
          <group group_id="O1">
            <title>IQP-AK-102</title>
            <description>2 capsules per dose, three times daily
IQP-AK-102</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 capsules per dose, 3 times daily
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Global Evaluation of Efficacy by the Investigators</title>
          <population>The analysis is performed for all subjects of the Intention-to-treat population who answered the questions for the assessment. However, missing data still appeared.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Evaluation of Efficacy by the Subjects</title>
        <time_frame>12 weeks</time_frame>
        <population>The analysis is performed for all subjects of the Intention-to-treat population who answered the questions for the assessment. However, missing data still appeared.</population>
        <group_list>
          <group group_id="O1">
            <title>IQP-AK-102</title>
            <description>2 capsules per dose, three times daily
IQP-AK-102</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 capsules per dose, 3 times daily
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Global Evaluation of Efficacy by the Subjects</title>
          <population>The analysis is performed for all subjects of the Intention-to-treat population who answered the questions for the assessment. However, missing data still appeared.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Evaluation of Safety by the Investigators</title>
        <time_frame>12 weeks</time_frame>
        <population>The analysis is performed for all subjects of the Intention-to-treat population who answered the questions for the assessment. However, missing data still appeared.</population>
        <group_list>
          <group group_id="O1">
            <title>IQP-AK-102</title>
            <description>2 capsules per dose, three times daily
IQP-AK-102</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 capsules per dose, 3 times daily
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Global Evaluation of Safety by the Investigators</title>
          <population>The analysis is performed for all subjects of the Intention-to-treat population who answered the questions for the assessment. However, missing data still appeared.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Evaluation of Safety by the Subjects</title>
        <time_frame>12 weeks</time_frame>
        <population>The analysis is performed for all subjects of the Intention-to-treat population who answered the questions for the assessment. However, missing data still appeared.</population>
        <group_list>
          <group group_id="O1">
            <title>IQP-AK-102</title>
            <description>2 capsules per dose, three times daily
IQP-AK-102</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 capsules per dose, 3 times daily
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Global Evaluation of Safety by the Subjects</title>
          <population>The analysis is performed for all subjects of the Intention-to-treat population who answered the questions for the assessment. However, missing data still appeared.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the treatment period ie. 12 weeks.</time_frame>
      <desc>The causality of the AEs and intake of IP was assessed by the clinician.
Three subjects who were excluded (due to violation of inclusion/exclusion criteria, and treatment compliance) in the Intention-to-treat population were included in the adverse events analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>IQP-AK-102</title>
          <description>2 capsules per dose, three times daily
IQP-AK-102</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>2 capsules per dose, 3 times daily
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <description>Improbable relation to Investigational product</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal complaints</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Nausea &amp; Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Toothache or dental extraction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Headaches and Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Distortion and contusion of knee</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Sciatica (Dorsalgia)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Infection of urinary tract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Common cold or upper respiratory tract infection</sub_title>
                <description>Light to moderate</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Allergic Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Abcess of the skin</sub_title>
                <description>In the breastbone area</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pee-Win Chong</name_or_title>
      <organization>InQpharm Europe Ltd</organization>
      <phone>+603 6201 9690 ext 358</phone>
      <email>pwchong@inqpharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

